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Background: The Canadian province of Manitoba covers a large geographical area but only has one major urban
center, Winnipeg. We sought to determine if regional differences existed in the quality of colorectal cancer care in a
publicly funded health care system.
Methods: This was a population-based historical cohort analysis of the treatment and outcomes of Manitobans
diagnosed with colorectal cancer between 2004 and 2006. Administrative databases were utilized to assess quality
of care using published quality indicators.
Results: A total of 2,086 patients were diagnosed with stage I to IV colorectal cancer and 42.2% lived outside of
Winnipeg. Patients from North Manitoba had a lower odds of undergoing major surgery after controlling for other
confounders (odds ratio (OR): 0.48, 95% confidence interval (CI): 0.26 to 0.90). No geographic differences existed in
the quality measures of 30-day operative mortality, consultations with oncologists, surveillance colonoscopy, and
5-year survival. However, there was a trend towards lower survival in North Manitoba.
Conclusion: We found minimal differences by geography. However, overall compliance with quality measures is
low and there are concerning trends in North Manitoba. This study is one of the few to evaluate population-based
benchmarks for colorectal cancer therapy in Canada.
Keywords: Colorectal cancer, Quality of care, Geography, ManitobaBackground
Canadian health care is publicly administered and uni-
versal for all insured residents [1]. However, authors
have raised concern over suboptimal or unequal access
and quality of health care among certain Canadian
populations [2,3]. In Manitoba, colorectal cancer (CRC)
is the third most common malignancy and poses a major
public health issue [4]. Manitoba covers a large geo-
graphic area with 56.5% of the population living in the
major urban center of Winnipeg [5,6]. Most cancer
patients in Manitoba are referred to the provincially
mandated agency, CancerCare Manitoba (CCMB), for* Correspondence: amckay3@exchange.hsc.mb.ca
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reproduction in any medium, provided the orconsideration of neoadjuvant and adjuvant therapies,
such as chemotherapy and radiation therapy. Two tertiary
locations are found in Winnipeg, while other non-tertiary
affiliated sites, providing chemotherapy, are found within
both Winnipeg and several communities in rural Manitoba
[7]. Although surgical facilities are present in both
Winnipeg and rural Manitoba, the only radiation therapy
unit, during the study period, was at the tertiary location of
CCMB in Winnipeg. For a large proportion of Manitobans,
access to specialized medical or surgical care requires trav-
elling great distances, personal expense, and inconvenience
as medical specialists are less frequently found in remote
and rural environments.
Since the quality of treatment for CRC has recently
become an important area for research and quality im-
provement initiatives [8-10], authors have developed a
set of quality indicators for CRC treatment [11]. QualityLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patterns and allow opportunities for improvement [12].
Utilization and application of quality indicators permits
benchmarking between institutions.
To date, there has been no formal analysis of the qual-
ity of CRC therapy in Manitoba using published quality
measures. We sought to assess whether geographic dif-
ferences existed in CRC quality of care. This study has
important implications for Canada and other jurisdic-
tions around the world that face similar challenges in of-
fering specialized health care to rural populations over
great distances.
Methods
The Health Research Ethics Board (HREB) at the Uni-
versity of Manitoba, MB, Canada, approved this study. A
population-based historical cohort analysis of all patients
diagnosed with adenocarcinoma of the colon or rectum
between 1 January 2004 and 31 December 2006 was
undertaken to examine the presentation, treatments, and
outcomes of CRC in Manitoba. Patients were identified
using the population-based Manitoba Cancer Registry
(MCR), maintained by CCMB. Information regarding all
Manitobans diagnosed with a malignancy is collected by
the MCR as cancer reporting is mandatory by Manitoba
law [13]. The MCR was used to identify patients based
on the International Statistical Classification of Diseases
and Related Health Problems, 10th Revision (ICD-10).
Patients who were diagnosed with CRC at the same date
as death, through autopsy or radiographic findings, were
excluded (n = 3).
From the MCR, demographic and tumor-specific
information, such as collaborative American Joint Com-
mittee on Cancer (AJCC) stage, were extracted. Patient-
specific data from the MCR was linked to information in
the Medical Claims (physician billing) database and the
Hospital Discharge Abstracts database. Although health
care utilization can be followed longitudinally, patient
information was linked using encrypted personal health
information numbers to maintain patient confidentiality.
These databases are maintained by Manitoba Health, the
agency responsible for providing health care to virtually
all Manitobans, and contain patient-specific information
about health care system contacts.
For treatment information from the MCR, the Inter-
national Classification of Diseases, 9th Revision, Clinical
Modification (ICD-9-CM) and the Canadian Classifica-
tion of Health Interventions (CCHI) coding were used
[14]. All treatment information was ascertained from
within 1 year of diagnosis of CRC. Index surgical proce-
dures, identified from the MCR, were classified in a
hierarchical pattern into: major surgery, local resections,
polypectomy, and none. The level of agreement for sur-
gical procedures between the MCR and administrativerecords from Manitoba Health was determined using
Fleiss’ kappa.
The quality of CRC care was assessed using previously
published quality indicators, developed by a multidiscip-
linary panel using a 3-step modified Delphi approach
[11]. A subset of these indicators was chosen on the
ability to accrue data from administrative databases.
Perioperative total colonic examination
For patients who underwent a major surgical resection,
the proportion who had a colonoscopy alone or a bar-
ium/contrast enema in conjunction with sigmoidoscopy
3 months prior or within 6 months after major surgery
was determined [11,15].
Anastomotic leak/early reoperation rate
No diagnostic code currently exists for anastomotic leaks
after surgery. To estimate this rate, surrogate markers
were utilized. For patients who underwent a major surgery
with an anastomosis that had one of the following proce-
dures during the same hospital stay, an anastomotic leak
was assumed: percutaneous or operative drainage of an
intra-abdominal abscess, laparotomy or laparoscopy post
major surgery, or ostomy formation post major surgery.
Although a laparotomy or laparoscopy in the postopera-
tive period may have been indicated for other complica-
tions, such as bleeding or obstruction, these were included
as early reoperation also represents a quality measure.
Extent of lymphadenectomy
Using the MCR, we assessed the median number of
lymph nodes analyzed for patients undergoing a major
surgical resection and the proportion of patients in which
greater than 12 lymph nodes were examined [16-19].
Medical and radiation oncology consultations for patients
with rectal cancer
The proportion of all patients with stage I to IV, as well
as stage II and III, rectal cancer who had been seen by a
medical and/or a radiation oncologist 3 months prior to
major surgery was determined from the MCR. In addition,
the proportion of patients with stage II or III disease seen
within 8 weeks, as well as within 16 weeks, of major sur-
gery was reported.
Medical oncology consultations for patients with colon
cancer
The proportion of patients with stage III colon cancer
who had been seen by a medical oncologist within 8
weeks and 16 weeks of surgery was determined.
Thirty-day mortality
The 30-day mortality rate after colon or rectal cancer
major surgery was determined.
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For patients who underwent a major surgery, we deter-
mined the proportion of patients, who were alive, and
who underwent a surveillance colonoscopy within 12
months and 14 months after the surgery date. The 1-year
post surgery surveillance colonoscopy is recommended by
the National Comprehensive Cancer Network (NCCN)
[20,21] and has been prioritized to be a quality measure
by an expert multidisciplinary panel [11].
Five-year overall survival rate
The 5-year overall absolute Kaplan-Meier survival esti-
mates from date of diagnosis to death, was determined







Mean age in years (range) 70 ± 13.00 70 ± 13.21 65 ±
(20 to 103) (25 to 103) (31
Age group (n (%))
>70 years 1,182 (56.66) 695 (57.63) 25
<70 years 904 (43.34) 511 (42.37) 40
Age quartilesa (n (%))
Quartile 1 542 (25.98) 324 (26.87) 27
Quartile 2 522 (25.02) 282 (23.38) 17
Quartile 3 530 (25.41) 312 (25.87) 12
Quartile 4 492 (23.59) 288 (23.88) 9 (
Gender (n (%))
Female 963 (46.16) 576 (47.76) 29
Male 1,123 (53.84) 630 (52.24) 36
Diagnosis year (n (%))
2004 706 (33.84) 413 (34.25) 20
2005 671 (32.17) 389 (32.26) 25
2006 709 (33.99) 404 (33.50) 20
Site (n (%))
Colon 1,376 (65.96) 788 (65.34) 44
Rectosigmoid 202 (9.68) 116 (9.62) 7 (
Rectum 508 (24.35) 302 (25.04) 14
AJCC stage (n (%))
I 403 (19.32) 226 (18.74) 7 (
II 575 (27.56) 334 (27.69) 19
III 610 (29.24) 364 (30.18) 15
IV 439 (21.05) 255 (21.14) 20
Unknown/NAb (n (%)) 59 (2.83) 27 (2.24) 4
aQuartile 1: age 20 years to 61 years, quartile 2: age greater than 61 years to 72 yea
than 80 years to 103 years; bone or more elements of the AJCC stage is missing or
value instead of direct P value computations, since the sample size is large and som
CRC colorectal cancer, NA not applicable, RHA regional health authority.Geographical comparisons were made between Winnipeg
and rural Manitoba, as well as between groupings of
Manitoba’s regional health authorities (RHAs): Winnipeg,
North Manitoba, South Manitoba, and Middle Manitoba.
Manitoba’s RHAs are regional governances whose responsi-
bility is to administer and deliver health services to speci-
fied geographic regions of the province [22].
Standard descriptive statistics and treatment frequency
information were reported. Treatment information from
the MCR was compared to the information taken from
the Hospital Discharge Abstracts to check the validity of
the data. Conventional stepwise multivariate logistic re-
gression was used to determine variables associated with









13.06 70 ± 13.08 71 ± 11.80 0.004
to 92) (20 to 94) (39 to 94)
(38.46) 277 (55.85) 185 (57.99) 0.022
(61.54) 219 (44.15) 134 (42.01)
(41.54) 129 (26.01) 62 (19.44) 0.004
(26.15) 120 (24.19) 103 (32.29)
(18.46) 128 (25.81) 78 (24.45)
13.85) 119 (23.99) 76 (23.82)
(44.62) 223 (44.96) 135 (42.32) 0.323
(55.38) 273 (55.04) 184 (57.68)
(30.77) 164 (33.06) 109 (34.17) 0.932
(38.46) 156 (31.45) 101 (31.66)
(30.77) 176 (35.48) 109 (34.17)
(67.69) 336 (67.74) 208 (65.20) 0.486
10.77) 54 (10.89) 25 (7.84)
(21.54) 106 (21.37) 86 (26.96)
10.77) 114 (22.98) 56 (17.55) 0.069c
(29.23) 139 (28.02) 83 (26.02)
(23.08) 134 (27.02) 97 (30.41)
(30.77) 95 (19.15) 69 (21.63)
(6.15) 14 (2.82) 14 (4.39)
rs, quartile 3: age greater than 72 years to 80 years, and quartile 4: age greater
staging scheme is not applicable; cusage of Monte-Carlo estimation of exact P
e cell values are less than five. AJCC American Joint Committee on Cancer,
Table 2 Stepwise multivariate logistic regression for
occurrence of a major surgical resection using RHA group
Variable Adjusted ORa 95% CI P value
Site <0.0001
Colon 1
Rectosigmoid 0.76 0.51 to 1.14
Rectum 0.53 0.40 to 0.70
AJCC stage <0.0001
I 1
II 4.11 2.83 to 5.97
III 5.97 3.87 to 9.20
IV 0.34 0.24 to 0.48
Unknown/NAb 0.09 0.04 to 0.19
Income quintilec 0.045
Quintile1 1
Quintile 2 1.04 0.73 to 1.48
Quintile 3 1.37 0.94 to 1.98
Quintile 4 1.41 0.96 to 2.07
Quintile 5 1.26 0.85 to 1.86
NF 0.32 0.11 to 0.93
CCI group 0.045
CCI count <1 1
CCI count = 1 1.39 1.00 to 1.93
CCI count >1 0.96 0.68 to 1.35
RHA group 0.037
Winnipeg 1
North Manitoba 0.48 0.26 to 0.90
South Manitoba 1.25 0.93 to 1.69
Middle Manitoba 1.11 0.78 to 1.57
Potential covariates in the model included: age group (<70 years, >70 years),
gender, site (colon, rectosigmoid, rectum), AJCC stage, income quintile,
Charlson comorbidity index (CCI) group, and RHA group. Age and gender were
not significant in the stepwise analysis.
aThe higher the odds ratio, the higher the odds of undergoing major surgery;
bone or more elements of the AJCC stage is missing or staging scheme is NA;
cquintile 1: poorest, quintile 5: richest, NF: patients for whom income quintile
information was not found, including patients living in institutionalized
facilities, such as personal care homes, mental health institutes, prisons, or
offices of the public trustee. AJCC American Joint Committee on Cancer, CCI
Charlson comorbidity index, CI confidence interval, NA not applicable, NF not
formatted, OR odds ratio, RHA regional health authority.
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analysis. The Cox proportional hazards regression model
was used to determine variables associated with overall
survival. Significance was set at α = 0.05. SAS statistical
software, versions 9.1 and 9.2 (SAS Institute Inc, Cary,
NC, USA), was used for data management and statistical
analyses.
Results
Between 2004 and 2006, 2,086 patients were diagnosed
with stage I to IV adenocarcinoma-based CRC. Table 1
lists patient demographic information and comparisons
by RHA group. There was relatively equal distribution of
patients diagnosed between 2004 and 2006. A higher
proportion of younger patients and a trend towards
more advanced stage at presentation were noted for pa-
tients from North Manitoba.
Of all patients diagnosed with CRC, 78.04% (n =
1,628) underwent a major surgery. Fifty-eight patients
(2.78%) underwent a local resection, while 70 patients
(3.35%) underwent a polypectomy alone. A total of 330
patients (15.82%) did not have any surgical intervention
(neither major surgery, local resection, nor polypectomy).
Predictors of major surgery were analyzed using a step-
wise multivariate logistic regression (Table 2). Patients di-
agnosed with rectal cancer, stage IV disease, and those
from North Manitoba were at a lower odds of undergoing
major surgery (odds ratio (OR): 0.48, 95% confidence
interval (CI): 0.26 to 0.90, P = 0.037). Fleiss’ kappa level of
agreement between the MCR and Hospital Discharge Ab-
stracts was 0.788 for overall surgical categories (major sur-
gery: 0.821, local resection: 0.615, polypectomy: 0.606, and
none: 0.821).
Quality measures and geographic variations are shown
in Table 3. The postoperative (30-day) mortality rate was
3.8%. Overall, 75.6% of patients (1,230/1,628) had peri-
operative total colonic examination. There were 217 pa-
tients (13.3%) that did not have any colonic/endoscopic
imaging before or after surgery. The extent of lymphade-
nectomy could be determined for 96.5% of patients
undergoing resection.
The 5-year overall survival for all patients diagnosed
with CRC between 2004 and 2006 was 49.9%. There was
no significant difference based on geography in Manitoba,
although a trend towards decreased survival for patients
in North Manitoba was observed (Figure 1). The multi-
variate Cox proportional hazards model analysis for 5-
year overall survival is shown in Table 4.
Discussion
In Manitoba, between 2004 and 2006, there was minimal
geographic variation of certain quality measures for CRC.
However, overall compliance with many quality measures
appears low. Addressing these issues is paramount inorder to provide all Manitobans with coordinated, high
quality care.
It was hypothesized that differences in access to cancer
care could manifest with rural patients presenting with
higher stage disease. This hypothesis was not confirmed.
However, there was a trend towards a higher stage in pa-
tients from North Manitoba. This observation is of con-
cern and requires further research.
Over 78% of patients underwent a major surgery, simi-
lar to findings in Ontario, Canada [23]. After controlling
Table 3 Quality measures for patients diagnosed with CRC between 2004 and 2006, and comparisons by geography
Geographic variation RHA group











(n/N) (n/N) (n/N) (n/N)
Total colonic examination 75.55% 75.08% 76.20% 0.604 75.08% 65.00% 74.00% 81.53% 0.049
(1,230/1,628) (705/939) (525/689) (705/939) (26/40) (296/400) (203/249)
Anastomotic leak/reoperation rate 1.72% 2.17% 1.13% 0.168 2.17% 2.94% 1.34% 0.51% 0.355a
(21/1,220) (15/691) (6/529) (15/691) (1/34) (4/298) (1/197)
Extent of lymphadenectomy
>12 lymph nodes 68.75% 69.07% 68.31% 0.749 69.07% 58.97% 72.42% 63.22% 0.054
(1,080/1,571) (623/902) (457/669) (623/902) (23/39) (281/388)
Positive lymph node status 45.47% 45.76% 45.09% 0.790 45.76% 48.72% 43.48% 47.11% 0.781
(719/1,581) (416/909) (303/672) (416/909) (19/39) (170/391) (114/242)
Medical oncology for rectal cancer
Stage I to IV preoperative consultation 13.15% 12.90% 13.51% 0.866 12.90% 28.57% 13.51% 11.94% 0.668
(48/365) (28/217) (20/148) (28/217) (2/7) (10/74) (8/67)
Stage II/III preoperative consultation 16.25% 14.48% 18.95% 0.359 14.48% 40.00% 22.73% 13.04% 0.250
(39/240) (21/145) (18/95) (21/145) (2/5) (10/44) (6/46)
Stage II/III seen within 8 weeks of
major surgery
36.25% 37.24% 34.74% 0.693 37.24% 40.00% 43.18% 26.09% 0.382
(87/240) (54/145) (33/95) (54/145) (2/5) (19/44) (12/46)
Stage II/III seen within 16 weeks of
major surgery
63.33% 63.45% 63.16% 0.964 63.45% 60.00% 77.27% 50.00% 0.065
(152/240) (92/145) (60/95) (92/145) (3/5) (34/44) (23/46)
Radiation oncology for rectal cancer
Stage I to IV preoperative consultation 17.81% 18.43% 16.89% 0.706 18.43% 14.29% 18.92% 14.93% 0.906
(65/365) (40/217) (25/148) (40/217) (1/7) (14/74) (10/67)
Stage II/III preoperative consultation 22.50% 23.45% 21.05% 0.664 23.45% 20.00% 27.27% 15.22% 0.559
(54/240) (34/145) (20/95) (34/145) (1/5) (12/44) (7/46)
Stage II/III seen within 8 weeks of
major surgery
31.25% 33.79% 27.37% 0.294 33.79% 0% 27.27% 30.43% 0.384
(75/240) (49/145) (26/95) (49/145) (0/5) (12/44) (14/46)
Stage II/III seen within 16 weeks of
major surgery
67.08% 68.28% 65.26% 0.627 68.28% 40.0% 77.27% 56.52% 0.105
(161/240) (99/145) (62/95) (99/145) (2/5) (34/44) (26/46)
Stage III colon cancer seen within
8 weeks of surgery
27.27% 27.35% 27.15% 0.966 27.35% 55.56% 28.92% 20.34% 0.160
(102/374) (61/223) (41/151) (61/223) (5/9) (24/83) (12/59)
Stage III colon cancer seen within
16 weeks of surgery
50.80% 47.09% 56.29% 0.081 47.09% 77.78% 63.86% 42.37% 0.011
(190/374) (105/223) (85/151) (105/223) (7/9) (53/83) (25/59)
30-day mortality 3.75% 4.05% 3.34% 0.506^ 4.05% 2.5% 4.00% 2.41% 0.643^
(61/1,628) (38/939) (23/689) (38/939) (1/40) (16/400) (6/249)
Surveillance colonoscopy within 12
months of surgery
29.62% 30.06% 29.02% 0.674 30.06% 25.00% 31.33% 26.05% 0.535
(410/1,384) (242/805) (168/579) (242/805) (8/32) (104/332) (56/215)
Surveillance colonoscopy within 14
months of surgery
45.37% 47.22% 42.81% 0.106 47.22% 32.26% 45.12% 40.76% 0.167
(618/1,362) (374/792) (244/570) (374/792) (10/31) (148/328) (86/211)
aUsage of Monte-Carlo estimation of exact P value instead of direct P value computations, since the sample size is large and some cell values are less than five;
^death within 30 days compared to death after 30 days and patients who were still alive. CRC colorectal cancer, RHA regional health authority.
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Manitoba at the time of diagnosis was associated with a
lower chance of undergoing surgery. Both system- andpatient-related factors could explain this disparity. Patient-
related factors in health decision making may be numer-
ous, including age, gender, education, emotional support,
Figure 1 Kaplan-Meier 5-year survival estimate by RHA group.
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aversion to postoperative complications may influence
patients to not seek or receive therapy [25,26]. Humber
and Dickinson examined rural patients’ experiences of
accessing surgery in British Columbia, Canada [27]. They
determined that rural patients prefer individualized care
in familiar environments. Transportation and financial
barriers were noted to be detrimental factors. Rural pa-
tients may be viewed as a culture with their own health
determinants and challenges in accessing health care [28].
The psychological effects of a cancer diagnosis com-
pounded with the need to travel to new environments in
order to access specialist care can be profound and may
deter patients from seeking therapies. System-related
factors, such as barriers to timely referral to surgeons,
or patients being offered different treatments may also
play a role.
Perioperative total colonic examination is important,
since the reported incidence of synchronous colonic le-
sions ranges from 2.12% to 8.1% [29-33]. In Manitoba,
75.6% of patients met this quality measure, similar to a
study from Nova Scotia, Canada [10]. Rates of total co-
lonic examination were lower in North Manitoba. It can
be hypothesized that this may relate to endoscopy access
issues. Also, patients may present emergently and be
unable to undergo full preoperative evaluation, and sub-
sequently not undergo evaluation postoperatively. It is
concerning that in our analysis, 13.3% of patients did
not have any colonic investigations. The underlying
reasons are unknown, but present an important area for
further research. Additionally, our reported rate of sur-
veillance colonoscopy within 1 year of surgery of 29.62% is
lower than that reported by other authors [16].Adequate lymphadenectomy is a well-established qual-
ity measure of colorectal cancer care for its vital role in
appropriate staging [17,34]. Lymph node status is a
strong predictor of survival outcomes in non-metastatic
CRC and implies the need for adjuvant therapy [17,35-38].
Patients who had greater than 12 lymph nodes examined
did, in fact, have a lower risk of mortality in this analysis.
Adequate lymphadenectomy may provide both a direct
therapeutic benefit, and improve staging accuracy and
prognosis [39]. A total of 68.8% of patients had adequate
nodal evaluation, as reflected by more than 12 lymph
nodes examined in pathology specimens. This rate is
higher than that reported by others [10,16-18], yet still
presents an opportunity for improvement.
Timely and appropriate assessment of patients diag-
nosed with rectal cancer by medical and radiation oncol-
ogy, either preoperatively or within 8 weeks of surgery,
is an important quality measure [11]. Previous studies
have been unable to determine rates of consultation, and
instead reported the proportion of patients that received
radiation or chemotherapy [16]. Reporting rates of con-
sultation presents a more accurate measure of quality of
care. The rates of assessment by medical and radiation
oncology within 8 weeks for patients with rectal cancer
are quite low. Others have reported higher rates [10,40].
When extending the timeframe to 16 weeks, the rate of
consultation with medical and radiation oncology nearly
doubled. This suggests that referrals are being made ap-
propriately but system limitations may account for un-
due delays in patients being seen. Referral delays, wait
lists, and pathology reporting delays may contribute to
lower than expected adherence with the quality measures,
and could explain the increased rate of patients seen






95% CI P value
Age quartileb <0.0001
Quartile 1 210 (38.75) 1
Quartile 2 234 (44.83) 1.21 1.00 to 1.46
Quartile 3 266 (50.19) 1.59 1.31 to 1.93
Quartile 4 328 (66.67) 2.07 1.69 to 2.53
Gender 0.007
Female 470 (48.81) 1
Male 568 (50.58) 1.19 1.05 to 1.35
Site 0.755
Colon 707 (51.38) 1
Rectosigmoid 103 (50.99) 1.06 0.85 to 1.31
Rectum 228 (44.88) 0.96 0.81 to 1.15
AJCC stage <0.0001
I 111 (27.54) 1
II 188 (32.70) 1.44 1.12 to 1.86
III 279 (45.74) 2.22 1.71 to 2.87
IV 412 (93.85) 7.67 5.88 to 10.00
Unknown/NAc 48 (81.36) 3.08 2.14 to 4.45
Income quintiled 0.004
Quintile 1 271 (58.66) 1
Quintile 2 240 (52.86) 1.07 0.90 to 1.28
Quintile 3 209 (47.83) 0.95 0.79 to 1.14
Quintile 4 159 (42.51) 0.92 0.75 to 1.13
Quintile 5 137 (40.90) 0.77 0.63 to 0.95
NF 22 (91.67) 1.78 1.14 to 2.78
CCI group <0.0001
CCI count <1 235 (28.08) 1
CCI count = 1 448 (58.56) 2.03 1.70 to 2.42
CCI count >1 355 (73.35) 2.79 2.33 to 3.36
RHA group 0.314
Winnipeg 589 (48.84) 1
North Manitoba 36 (55.38) 0.98 0.69 to 1.39
South Manitoba 239 (48.19) 1.16 0.99 to 1.35
Middle Manitoba 174 (54.55) 1.04 0.87 to 1.23
Surgery <0.0001
Major surgery 694 (42.63) 0.54 0.40 to 0.73
Local resection 14 (24.14) 0.33 0.18 to 0.58
Polypectomy 26 (37.14) 0.63 0.40 to 0.97
None 304 (92.12) 1
Chemotherapy <0.0001
No 677 (50.52) 1
Yes 361 (48.39) 0.59 0.50 to 0.69
Table 4 The 5-year overall survival Cox proportional
multivariate hazards model (Continued)
Radiation therapy 0.126
No 916 (51.29) 1




0 to 12 249 (47.43) 1
>12 440 (39.43) 0.76 0.65 to 0.89
Unknown/not
examinede
349 (78.43) 1.43 1.06 to 1.94
All variables listed are included in the full model. aHR >1 relates to higher
mortality; bquartile 1: age 20 years to 61 years, quartile 2: age greater than 61
years to 72 years, quartile 3: age greater than 72 years to 80 years, and
quartile 4: age greater than 80 years to 103 years; cone or more elements of
the AJCC stage is missing or staging scheme is NA; dquintile 1: poorest,
quintile 5: richest; eunknown number or no lymph nodes examined.
AJCC American Joint Committee on Cancer, CCI Charlson comorbidity index,
CI confidence interval, HR hazards ratio, NA not applicable, NF not formatted,
RHA regional health authority.
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ation therapy services were only available at a single center
in Winnipeg, necessitating travel for rural patients. In
addition, the proportion of patients with rectal cancer seen
preoperatively by radiation oncology was low, possibly
because the timeframe of this study predated the general
trend from adjuvant to neoadjuvant chemoradiation
treatment [41].
For patients diagnosed between 2004 and 2006,
Manitoba’s population-based 5-year overall survival was
49.9%. Initially, this appears to be lower than previously
reported [16,42]. However, comparisons must be made
cautiously. Vergarara-Fernandez et al. reported a 5-year
overall survival rate of 75% at a single, high volume
tertiary center [16]. Population-based absolute survival
rates are presented in our study. Most notably, no geo-
graphic differences in 5-year survival were demonstrated.
However, though not statistically significant, a trend to-
wards a lower 5-year overall Kaplan-Meier survival rate
for patients from North Manitoba was noted. This trend
highlights an important area for future research.
This study is limited by the retrospective collection of
administrative data, which may contain incomplete re-
cords and coding errors [43-45]. However, the MCR has
been demonstrated to be among the highest quality ad-
ministrative cancer databases [46]. Based on the study
design, patients’ preferences could not be accounted for.
Additionally, we were unable to report relative survival
rates to control for underlying mortality in each RHA
group. This limits the ability to draw comparisons to
other population-based survival analyses. Furthermore,
we were unable to account for racial differences in
outcomes in this analysis. However, this is the first
Manitoban study to provide comprehensive CRC quality
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poral and interprovincial comparisons. Additionally, there
was a high level of agreement between the MCR and the
administrative databases maintained by Manitoba Health
for surgical treatment information. This finding may allow
for future studies to use the MCR for surgical cancer
treatment information.
We have identified concerning findings in North
Manitoba, such as the lower odds of receiving major
surgery, while accounting for stage and other con-
founders, and lower rates of total colonic examination.
The trend towards lower survival and higher stage in
North Manitoba is very concerning. Given that only 65
patients were from North Manitoba, this study suffered
from lack of power when analyzing this subset of the
population further. The MCR only began collecting de-
tailed TNM staging information in 2004, preventing the
addition of earlier years to the study data. Future ana-
lyses, including later time periods, beyond 2006, will be
undertaken to better delineate the findings for patients
in North Manitoba. However, these findings are import-
ant and should be shared with other jurisdictions that
share similar geographical challenges in providing high
quality care for CRC and other medical problems. Focus
should be placed on addressing access, surgical issues,
such as patients’ preferences, in addition to system-
based barriers for patients living in locations remote
from major urban centers. Further research on rural pa-
tients’ perspectives of surgery is warranted.
Conclusion
Although minimal geographic differences in quality mea-
sures were seen, overall adherence was less than ideal.
Further research is necessary to better delineate the rea-
sons for this. This research is important in its implication
for Manitoba’s health care system, as well as for the rest of
Canada, and other areas of the world that might face
similar challenges in providing high quality cancer care to
rural patients over significant distances.
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